Skip to main content
. 2018 Dec 19;7(3):597–618. doi: 10.1016/j.jcmgh.2018.12.004

Figure 14.

Figure 14

Schematic illustration of metabolic responses in the liver from mice treated with GalNAc-Stk25 ASO vs GalNAc-control ASO. Treatment with hepatocyte-specific GalNAc-conjugated Stk25 ASO effectively ameliorated high-fat-diet–induced liver steatosis, inflammatory infiltration, hepatic stellate cell (HSC) activation, nutritional fibrosis, and hepatocellular damage compared with mice treated with GalNAc-conjugated nontargeting ASO, without any systemic toxicity or local tolerability concerns.